Contraceptive Effectiveness of Sino-implant (II) in China
A Study to Evaluate the Contraceptive Effectiveness During the Third, Fourth and Fifth Year of Sino-implant (II) Use and the Pharmacokinetics Over Five Years of Use in Chinese Women
Przegląd badań
Status
Warunki
Szczegółowy opis
A Study to Evaluate the Contraceptive Effectiveness during the Third, Fourth and Fifth Year of Sino-implant (II)Use and the Pharmacokinetics (PK) over Five Years of use in Chinese Women
Population: A total of 590 Chinese Sino-Implant (II) users between 20and 44 years of age enrolled in one of four prospective cohorts:
Cohort 1: n=20 women with insertion dates 3-5months prior to enrollment and followed for 2-6 months Cohort 2:n=20 women with insertion dates 9-11 months prior to enrollment and followed for 2-6 months Cohort 3: n=250 women with insertion dates 21-24 months prior to enrollment and followed through month 36 Cohort 4:n=300 women with insertion dates 33-36 months prior to enrollment and followed through month 6
Study Duration: 33 total months in the field: 3 months of participant recruitment(all cohorts); up to 27 months of pregnancy monitoring and PK blood sampling in Cohort 4 (up to 15 months in Cohort 3 and 6 months in Cohort 1 and Cohort 2);and 3 months of close-out activities.
For secondary PK outcomes, blood samples will be taken 2 to 6 months apart from each woman in Cohort 1 and Cohort 2; at enrollment, month 30 and month 36 from the first 20 consenting women in Cohort 3; and at enrollment and months 42, 48, 54, and 60 from the first 30 consenting women in Cohort 4.
Primary Objective: To evaluate the contraceptive effectiveness of Sino-implant (II) during the third and fourth years of use
Secondary Objectives:
- To evaluate the contraceptive effectiveness of Sino-implant (II) during the fifth year of use.
- To characterize the total and free levonorgestrel (LNG) plasma concentration-time profiles over five years following Sino-implant (II) insertion
- To characterize the sex hormone binding globulin (SHBG) serum concentration-time profile and its relationship to total LNG levels over five years following Sino-implant (II) insertion
Typ studiów
Zapisy (Rzeczywisty)
Kontakty i lokalizacje
Lokalizacje studiów
-
-
-
Anyang, Chiny
- An Yang Population and Family Planning Service Station
-
Lingbao, Chiny
- Lingbao Population and Family Planning Service
-
Lushi, Chiny
- Lushi Family Planning Technical Service Station
-
Shanghai, Chiny
- Shanghai Institute of Planned Parenthood
-
Tongxiang, Chiny
- Tongxiang Population and Family Planning Service Station
-
-
Kryteria uczestnictwa
Kryteria kwalifikacji
Wiek uprawniający do nauki
Akceptuje zdrowych ochotników
Płeć kwalifikująca się do nauki
Metoda próbkowania
Badana populacja
Opis
Inclusion Criteria:
- Have a confirmed Sino-implant (II) set in place;
- Have a confirmed contraceptive implant insertion date consistent with the criteria for the cohort she is to be enrolled in;
- Be aged between 20 and 44 years, inclusive;
- Not wish to become pregnant in the next year;
- No desire to get implant removal within the next year;
- Be able to understand the information given to them and to make personal decisions on whether to participate or not in the study;
- Consent to participation and sign an informed consent form;
- Agree and be able to return to the clinic for follow-up visit(s).
Exclusion Criteria:
- Acute liver disease or cirrhosis by self-report;
- Benign or malignant tumor of the liver by self-report;
- Use of rifampicin, and/or anticonvulsants (barbiturates, phenytoin, phenobarbital, carbamazepine, oxcarbazepine, primidone, topiramate), and/or herbal products containing St. John's wort (Hypericum perforatum) by self-report;7
- Use of medications containing LNG or other hormones that impact LNG or SHBG disposition, e.g. treatment with LNG or oral contraceptives for bleeding disturbances by self-report;
- Known HIV-positive status by self-report;
- Any condition (social or medical) which in the opinion of the Investigator would make study participation unsafe, would interfere with adherence to study requirements, or complicate data interpretation.
Plan studiów
Jak projektuje się badanie?
Szczegóły projektu
Kohorty i interwencje
Grupa / Kohorta |
|---|
|
Cohort 1
n=20 women with insertion dates 3-5months prior to enrollment and followed for 2-6 months
|
|
Cohort 2
n=20 women with insertion dates 9-11 months prior to enrollment and followed for 2-6 months
|
|
Cohort 3
n=250 women with insertion dates 21-24 months prior to enrollment and followed through month 36
|
|
Cohort 4
n=300 women with insertion dates 33-36 months prior to enrollment and followed through month 6
|
Co mierzy badanie?
Podstawowe miary wyniku
Miara wyniku |
Opis środka |
Ramy czasowe |
|---|---|---|
|
Pregnancy Pearl Index
Ramy czasowe: 27 months
|
Pregnancy Pearl Index (number of pregnancies per 100 woman-years) during the third and fourth years of use, respectively, in Cohort 3 and Cohort 4
|
27 months
|
Miary wyników drugorzędnych
Miara wyniku |
Ramy czasowe |
|---|---|
|
Pregnancy Pearl Index during the fifth year of Sino implant (II) use
Ramy czasowe: 27 months
|
27 months
|
|
Total and free LNG plasma concentrations measured by a high-performance liquid chromatography with mass spectrometry assay
Ramy czasowe: 27 months
|
27 months
|
|
Serum SHBG concentrations measured by a chemiluminescence immunoassay
Ramy czasowe: 27 months
|
27 months
|
Współpracownicy i badacze
Sponsor
Współpracownicy
Śledczy
- Główny śledczy: Markus Steiner, Ph.D., FHI 360
Daty zapisu na studia
Główne daty studiów
Rozpoczęcie studiów
Zakończenie podstawowe (Rzeczywisty)
Ukończenie studiów (Rzeczywisty)
Daty rejestracji na studia
Pierwszy przesłany
Pierwszy przesłany, który spełnia kryteria kontroli jakości
Pierwszy wysłany (Oszacować)
Aktualizacje rekordów badań
Ostatnia wysłana aktualizacja (Oszacować)
Ostatnia przesłana aktualizacja, która spełniała kryteria kontroli jakości
Ostatnia weryfikacja
Więcej informacji
Terminy związane z tym badaniem
Inne numery identyfikacyjne badania
- 458241-1
Plan dla danych uczestnika indywidualnego (IPD)
Planujesz udostępniać dane poszczególnych uczestników (IPD)?
Te informacje zostały pobrane bezpośrednio ze strony internetowej clinicaltrials.gov bez żadnych zmian. Jeśli chcesz zmienić, usunąć lub zaktualizować dane swojego badania, skontaktuj się z register@clinicaltrials.gov. Gdy tylko zmiana zostanie wprowadzona na stronie clinicaltrials.gov, zostanie ona automatycznie zaktualizowana również na naszej stronie internetowej .